Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by
Roche. It is a
small molecule phosphoinositide 3-kinase inhibitor targeting the
PI3K isoform p110α (PIK3CA).
Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. Currently running clinical trials
[https://clinicaltrials.gov/ct2/results?term=taselisib&Search=Apply&recrs=d&age_v=&gndr=&type=&rslt=] were continued for patients exhibiting benefit.
References
Phosphoinositide 3-kinase inhibitors
Propionamides
Benzoxazepines
Abandoned drugs
{{antineoplastic-drug-stub